Shareholders to Vote on 900% Authorized Stock Increase and New Equity Plan

summarizeSummary

20/20 Biolabs, Inc. has filed its definitive proxy statement, setting the stage for a shareholder vote on proposals to increase authorized common stock by 900% and approve a new, highly dilutive equity incentive plan, against a backdrop of financial distress.

check_boxKey Events

• Shareholder Meeting Scheduled

  The Annual Meeting of Stockholders is scheduled for August 18, 2026, where critical proposals regarding the company's capital structure will be voted on.

• Massive Increase in Authorized Shares Proposed

  Shareholders will vote on an amendment to increase authorized common stock from 50 million to 500 million shares. This 900% increase could enable potential dilution of nearly 4000% relative to the current 12.25 million outstanding shares.

• Highly Dilutive Equity Incentive Plan

  A new 2026 Equity Incentive Plan is proposed, initially reserving 5 million shares (over 40% of current outstanding) with an automatic 7% annual increase based on outstanding shares, posing significant ongoing dilution risk.

• Finalizes Terms of Previously Announced Proposals

  This filing finalizes the specific terms and details of the authorized share increase and new equity incentive plan, which were previously outlined in a preliminary proxy statement on June 1, 2026.

auto_awesomeAnalysis

This definitive proxy statement formalizes the terms for shareholder approval of highly dilutive proposals, following a preliminary proxy filing. The company is seeking to increase its authorized common stock from 50 million to 500 million shares, a 900% increase that could lead to nearly 4000% potential dilution relative to current outstanding shares. Additionally, a new 2026 Equity Incentive Plan is proposed, initially reserving 5 million shares (over 40% of current outstanding) with an automatic 7% annual increase. These proposals are critical for a micro-cap company that has previously disclosed a 'going concern' warning and engaged in other highly dilutive financing activities, indicating a severe need for capital that will significantly impact existing shareholders.